Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429169 · ClinicalTrials.gov registry record · Phase 4
Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 4
- Development phase
- 101
- Enrollment target
NCT00429169 is a Phase 4 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 101 participants.
The verdict
NCT00429169, a Phase 4 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 101 participants
- Enrollment target
Study Summary
The primary study comparing effectiveness for suicidal ideation and/or behavior of two antidepressant medications in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts has been completed. A secondary study component using functional magnetic resonance imaging (fMRI) to investigate different medication effects on reward processing in the same sample is ongoing.
Interventions
- DRUG Bupropion
- DRUG Paroxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2004-06 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429169
The ClinicalTrials.gov registry entry for NCT00429169 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bupropion is the first listed.
NCT00429169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429169 about?
NCT00429169 is a clinical study titled "Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression". The primary study comparing effectiveness for suicidal ideation and/or behavior of two antidepressant medications in depressed patients who have attempted suicide or are currently experiencing suicidal thoughts has been completed. A secondary study component using functional magnetic resonance imag...
What is the current status of trial NCT00429169?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 101 participants. The study started on 2004-06. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00429169?
The interventions under investigation include: Bupropion (DRUG), Paroxetine (DRUG).
Who is sponsoring clinical trial NCT00429169?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.